Evidence map›Paper›PMID 26747026›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2016

Potential mechanisms for low uric acid in Parkinson disease.

Radhika Sampat, Sarah Young, Ami Rosen, Douglas Bernhard, David Millington, Stewart Factor, H A Jinnah

Abstract read
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Uric Acid in Parkinson's Disease: What Is the Connection?Movement disorders : official journal of the Movement Disorder Society · 2022
    Review
  7. Article
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Radhika SampatDepartment of Neurology, Emory University, Atlanta, GA, 30322, USA. rsampat@emory.edu.
Sarah YoungDepartment of Biochemistry, Duke University, Durham, NC, 27713, USA.
Ami RosenDepartment of Neurology, Emory University, Atlanta, GA, 30322, USA.
Douglas BernhardDepartment of Neurology, Emory University, Atlanta, GA, 30322, USA.
David MillingtonDepartment of Biochemistry, Duke University, Durham, NC, 27713, USA.
Stewart FactorDepartment of Neurology, Emory University, Atlanta, GA, 30322, USA.
H A JinnahDepartment of Neurology, Emory University, Atlanta, GA, 30322, USA. hjinnah@emory.edu.

Funding

Udall Parkinson's Disease Center at Emory University: Circuitry to TherapyP50NS071669 · NINDS · EMORY UNIVERSITY · PI WICHMANN, THOMAS · 2010 to 2015
$6.8M
NINDS NIH HHS P50 NS071669
6 · The paper itself

Abstract

Several epidemiologic studies have described an association between low serum uric acid (UA) and Parkinson disease (PD). Uric acid is a known antioxidant, and one proposed mechanism of neurodegeneration in PD is oxidative damage of dopamine neurons. However, other complex metabolic pathways may contribute. The purpose of this study is to elucidate potential mechanisms of low serum UA in PD. Subjects who met diagnostic criteria for definite or probable PD (n = 20) and controls (n = 20) aged 55-80 years were recruited. Twenty-four hour urine samples were collected from all participants, and both uric acid and allantoin were measured and corrected for body mass index (BMI). Urinary metabolites were compared using a twoway ANOVA with diagnosis and sex as the explanatory variables. There were no significant differences between PD and controls for total UA (p = 0.60), UA corrected for BMI (p = 0.37), or in the interaction of diagnosis and sex on UA (p = 0.24). Similarly, there were no significant differences between PD and controls for allantoin (p = 0.47), allantoin corrected for BMI (p = 0.57), or in the interaction of diagnosis and sex on allantoin (p = 0.78). Allantoin/UA ratios also did not significantly differ by diagnosis (p = 0.99). Our results imply that low serum UA in PD may be due to an intrinsic mechanism that alters the homeostatic set point for serum UA in PD, and may contribute to relatively lower protection against oxidative damage. These findings provide indirect support for neuroprotection trials aimed at raising serum UA.

Indexed as

AgedAged, 80 and overAllantoinFemaleHumansMaleMiddle AgedParkinson DiseaseUric AcidAllantoinUric AcidAllantoinMetabolismOxidative stressParkinson diseaseUric acid

Identifiers

PMID26747026
PMCPMC5912672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.